Le LÚzard
Classified in: Covid-19 virus
Subjects: Conference, Trade Show

Teva to Present New AJOVY« (fremanezumab) Analyses and Latest COPAXONE« Data (glatiramer acetate injection) at European Academy of Neurology Congress

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that new data on AJOVY« (fremanezumab) and the burden of migraine in Europe will be presented at the 6th Congress of the European Academy of Neurology (EAN), being held virtually from 23-26 May 2020. Additionally, Teva will present data on the long-term safety and efficacy of COPAXONE« (glatiramer acetate injection). This year's EAN congress is a virtual meeting due to the global coronavirus pandemic. All Teva abstracts will be published in a supplement to the European Journal of Neurology.

The new data, shared across nine ePresentations and three ePosters, reinforce the importance of continuing to study therapies that impact large patient populations. As the third-most prevalent disease in the world, affecting over one billion people globallyi, migraine imposes physical, emotional and societal burdens worldwideii,iii,iv,v,vi with limited treatment options available to many patients.

"Teva has a deep history in neurology and these data demonstrate our continued commitment to advancing solutions for patients with unmet needs," said Matthias Mueller, MD MSc, VP Global Medical Affairs - Global Therapeutic Areas and Scientific Communications, Teva. "We look forward to presenting these new data, which include pooled results of our AJOVY Phase 3 trials and a 7-year evaluation of COPAXONE. We are proud of our ongoing efforts in evaluating the social impact and burden of migraine. It is critically important to understand the global impact of migraine and we are committed to collecting real-world data that can educate the broader healthcare population. We are also committed to evaluating treatment options for patients living with multiple sclerosis (MS), as demonstrated by our analysis of the long-term efficacy and safety of COPAXONE."

The AJOVY data highlight data on safety, efficacy and quality-of-life for patients experiencing difficult-to-treat migraine as well as challenges posed by comorbidities and advancing age. The post-hoc analyses to be presented examine the data on AJOVY as reflected in the pooled analyses:

across the FOCUS, HALO-episodic migraine (EM) and HALO-chronic migraine (CM) Phase 3 clinical trials.

Teva will host an online symposium "Pathways to Change: Anti-CGRP Monoclonal Antibodies & the Evolving Migraine Prevention Landscape," on Sunday, 24 May from 13:45-14:45 CET. The symposium will be led by Messoud Ashina, Professor of Neurology in the Faculty of Health and Medical Sciences, University of Copenhagen, Denmark, and will review the considerable burden of migraine from a patient perspective, discussing insights for targeted prevention that can be gained from the latest research on the neurovascular pathophysiology of migraine.

Approximately 2.5 million people live with multiple sclerosis (MS) worldwidevii, and relapsing-remitting is the most common MS disease courseviii. Teva will also share new long-term efficacy and safety results of COPAXONE from the 7-year Glatiramer Acetate Low?Frequency Administration (GALA) open?label extension study.

The complete list of Teva presentations to be available at the congress can be found below. All ePresentations and ePoster sessions will be recorded in advance and available through the EAN conference website. The sessions will be available at no cost and will also be on-demand for EAN members from 27 May onward.

Please note presentation times below reflect the schedule at the time of publication; please refer to the EAN conference website for the final schedule.

AJOVY and Migraine Data:

Disease Burden



Patient Satisfaction

Cardiovascular Safety

Clinical Trial Protocol


Teva Online Symposium:

Teva Expert Sessions:
The below sessions are available as on-demand video presentations at the Teva medical affairs virtual booth on the EAN congress webpage.

Information for Europe about AJOVY«? can be found here.

?Adverse events should be reported.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events. Reporting forms and information can be found at https://www.hpra.ie. Adverse events should also be reported to Teva ? please refer to local numbers.

COPAXONE« (glatiramer acetate injection) is indicated for the treatment of patients with relapsing forms of multiple sclerosis. The most common side effects of COPAXONE« are redness, pain, swelling, itching, or a lump at the site of injection, flushing, rash, shortness of breath, and chest pain. See additional important information at: https://www.medicins.org.uk/emc/product/7046/smpc. For hardcopy releases, please see enclosed full prescribing information. The COPAXONE« brand is approved in more than 50 countries worldwide, including the United States, Russia, Canada, Mexico, Australia, Israel, and all European countries.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people's lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at www.tevapharm.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding new analysis of fremanezumab Injection and COPAXONE«, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:

and other factors discussed in our Quarterly Report on Form 10-Q for the first quarter of 2020 and our Annual Report on Form 10-K for the year ended December 31, 2019, including in the sections captioned "Risk Factors" and "Forward Looking Statements." Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

i Global Burden of Disease 2016 Disease and Injury Incidence and Prevalence Collaborators. Lancet 2017;390:1211?59.
ii Martelletti P, et al. J Headache Pain 2018;19:115.
iii D'Amico D, Tepper SJ. Neuropsychiatr Dis Treat 2008;4:1155?67
iv Lipton RB, et al. Neurology 2007;68:343?9.
v Gooch CL, et al. Ann Neurol 2017;81:479?84.
vi Linde M, et al. Eur J Neurol 2012;19:703?11.
vii Prevalence and incidence of multiple sclerosis. Multiple Sclerosis Trust. Updated February 2020. Accessed May 2020.
viii Types of MS. National Multiple Sclerosis Society. https://www.nationalmssociety.org/What-is-MS/Types-of-MS. Accessed May 2020.

These press releases may also interest you

at 10:10
In a time of restricted movement for most Americans, how has TV impacted advertisers' ability to drive digital engagement? To find out, Effectv, the advertising sales division of Comcast Cable, and TVSquared, a leader in TV attribution, released...

at 10:06
Dallas based metal shop NoContactKey recently announced its launch of their clean touch germ key for the gaming industry. The owner of the company, Don Douglas shares excitement as they help gamblers get back to the casinos....

at 10:05
The "Microwave Packaging - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering. The Global Microwave Packaging Market is expected to grow at a CAGR of 10.2% during the forecast period. Rise in requirement...

at 10:05
Technavio has been monitoring the unconventional gas market and it is poised to grow by USD 41.76 billion during 2020-2024, progressing at a CAGR of almost 7% during the forecast period. The report offers an up-to-date analysis regarding the current...

at 10:05
Warren, a Brazilian digital brokerage firm founded in 2017 in Porto Alegre, announced today that it has received a 120 million Reais investment led by QED Investors which has invested in companies including Nubank, Loft, Quinto Andar, Creditas,...

at 10:05
There is no shortage of personal protective equipment at Fusion PPE. Five months into the coronavirus pandemic and Fusion PPE continues to deliver authentic supplies to the healthcare industry and other businesses, contradictory to news of nationwide...

News published on 22 may 2020 at 02:05 and distributed by: